CCA Industries posts Q1 net loss, completes outsourcing move
EAST RUTHERFORD, N.J. — CCA Industries, whose portfolio includes Nutra Nail, Bikini Zone, Plus+White toothpaste and Scar zone scar treatment, posted a loss for the first quarter.
For the quarter ended Feb. 28, total revenues were $7.75 million and it posted a net loss of $1.24 million. This compares with revenues of $11.80 million and the net loss $1.02 million in the year-ago period. Basic and fully diluted losses per share for the quarter were 18 cents compared a loss of 14 cents for the same quarter last year.
"We are moving rapidly to leverage our new association with the Emerson Group to help increase our brand distribution base. This largely reflects the power of scale the Emerson Group brings to our company by managing over $1.7 billion in annual consumer sales against a variety of niche consumer product brands very similar to ours with the retailers in all classes of trade," stated Richard Kornhauser, CEO and President. "Moreover, and concurrently with the outsourcing effort, we have taken significant action to drive consumers to the shelves to purchase our brands by redeploying much of the cost savings achieved into added media and new harder working advertising that moves product. We have already seen a very positive response to our efforts in March as our renewed and enhanced marketing efforts reinforce our brand connection to the consumer. While the accelerated shift to outsourcing — achieved 30-days quicker than originally anticipated — is highly beneficial and delivers substantial cost savings to us through the year — it did lead to some logistical early challenges that impeded our business results in the first quarter of 2014. These issues are principally corrected. Importantly, we believe that the benefits of our efforts in totality will dramatically help drive brand awareness, enhance our distribution base, and improve in-store merchandising which we believe will prove highly positive starting in the second quarter and throughout fiscal 2014 and beyond.”
99 Cents Only reports $1.5 billion in sales over 10-month fiscal year
CITY OF COMMERCE, Calif. — 99 Cents Only Stores on Tuesday announced its financial results for the shortened fiscal year 2014 that began on March 31, 2013 and ended Jan. 31, 2014, consisting of 44 weeks.
For the 10 month fiscal 2014 the Company’s net sales totaled $1.5 billion. Same-store sales increased 3.7%, calculated on a comparable 43-week period of the prior year. Net loss was $12.5 million in fiscal 2014 and net loss as a percentage of net sales was (0.8)% in fiscal 2014.
"We are pleased with the progress we have made on implementing our strategic plan to accelerate store growth and improve sales and margin," stated Stephane Gonthier, CEO of the company. We are also encouraged by the favorable responses from our consumers to our ‘Go-Taller’ program, which has retrofitted the display shelving from a height of 54 inches to 78 inches at 64 of our stores in the past two months. We are on track to complete the retrofits by September 2014."
Average sales per store open at least 12 months, on a trailing 52-week period, increased to $5.4 million in fiscal 2014 from $5.3 million in fiscal 2013. Average net sales per estimated saleable square foot (computed for stores open at least 12 months) on a trailing 52-week period increased to $330 per square foot for fiscal 2014 from $321 per square foot for fiscal 2013.
As previously announced, the company changed its fiscal year from the Saturday closest to the end of March, to the Friday closest to the end of January, in order to be in line with its retail industry peers.
During the 10 month fiscal 2014, the company opened 27 net new stores. As of the end of fiscal 2014, 99 Cents Only operated 343 stores, an increase of 8.5% in store count over the end of fiscal 2013.
FDA sets advisory committee meeting for potential switch of Merck’s Singulair Allergy tablets
SILVER SPRING, Md. — The Food and Drug Administration on Friday announced a meeting of the Nonprescription Drugs Advisory Committee on May 2 to discuss the potential switch of Merck’s Singulair Allergy tablets.
The proposed OTC use is "temporarily relieves these symptoms due to hay fever or other upper respiratory allergies: Nasal congestion, runny nose, itchy, watery eyes, sneezing, itching of the nose.” The applicant proposes to label the product for OTC use in adults 18 years and older.
Prescription-only Singulair is currently used to treat outdoor allergies that happen part of the year (seasonal allergic rhinitis) in adults and children ages 2 years and older, and indoor allergies that happen all year (perennial allergic rhinitis) in adults and children ages 6 months and older.
As a prescription remedy, Singulair is also indicated to prevent asthma attacks and for the long-term treatment of asthma in adults and children ages 12 months and older, as well as to prevent exercise-induced asthma in people 6 years of age and older. However, there is nothing suggesting that OTC Singulair Allergy will be indicated to treat or prevent any asthma symptoms.